3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Endometrial Hyperplasia
2
Breast Neoplasms
2
Venous Thrombosis
1
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
pembrolizumab
2
Radiosurgery
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
FAPI-46
2
tipifarnib
1
sodium thiosulfate
1
sargramostim
1
regorafenib
1
montelukast
1
entrectinib
1
entinostat
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
alectinib
1
aflibercept
1
Trastuzumab
1
Thiotepa
1
Tablets
1
Specimen Handling
1
Sirolimus
1
Sevoflurane
1
Ritonavir
1
Restraint, Physical
1
Radiotherapy
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Atorvastatin
×
Gynecologic
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn